Zika Virus IgM Antibody Capture (MAC), by ELISA
Also known as: ZIKA M
Use
This test is used for patients whose symptoms began, or whose documented exposure occurred, at least 14 days prior to testing. It serves as a follow-up for patients with negative serum and urine results from molecular testing performed less than 14 days after symptom onset. The presence of detectable Zika IgM antibody indicates presumptive recent infection, and results of presumptive positive for other flavivirus(es) should be confirmed with an FDA-cleared dengue and West Nile virus IgM test.
Special Instructions
Parallel testing is preferred, and convalescent specimens must be received within 30 days from receipt of the acute specimens. Mark specimen plainly as 'acute or convalescent.' Submit patient history.
Limitations
The possibility of false-positive or false-negative results must be considered. RT-PCR testing on both a serum and urine specimen is recommended by the CDC to rule out false-negative IgM results in patients experiencing symptoms for less than 2 weeks. Specimens collected for IgM testing greater than or equal to 2 weeks after symptom onset do not require any additional testing.
FDA ApprovedNew York Approved
Methodology
Immunoassay (ELISA)
Biomarkers
LOINC Codes
- 80824-6
Result Turnaround Time
1-6 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2 mL
Minimum Volume
1.0 mL
Container
ARUP standard transport tube
Collection Instructions
Separate from cells ASAP or within 2 hours of collection. Transfer serum to an ARUP standard transport tube.
Storage Instructions
Refrigerated
Causes for Rejection
Bacterially contaminated, heat-inactivated, hemolyzed, icteric, lipemic, or turbid specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 2 weeks |
| Frozen | 1 year (avoid repeated freeze/thaw cycles) |